Trial
Dasatinib plus quercetin diabetic kidney disease pilot
Research Observatory
Evidence Update
Current evidence
The NCT02848131 pilot studied a brief course of dasatinib plus quercetin in people with diabetic kidney disease, without a randomized comparator. Eleven people enrolled; nine contributed adipose immunohistochemistry before and after treatment. These observations support only limited tissue-specific target engagement.
What changed
The correction—not the uncorrected article—governs sample counts and statistical conclusions.
What did not change
No control group or kidney-efficacy inference is added.
Why it matters
A trial record must expose the changed skin conclusion rather than generalize tissue clearance.
Main limitation
Paired reanalysis and composites in a small uncontrolled cohort.
Next proof
Controlled replication with validated tissue and clinical endpoints.
Summary
The NCT02848131 pilot enrolled 11 people; nine contributed adipose immunohistochemistry before and after a brief D+Q course.
Intelligence Take
A trial record must expose the changed skin conclusion rather than generalize tissue clearance.
Limitations
Paired reanalysis and composites in a small uncontrolled cohort.